Cargando…
Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation
OBJECTIVE: Extracellular ATP mediates mast cell-dependent intestinal inflammation via P2X7 purinoceptors. We have previously shown that CD300f (also called the leucocyte mono-immunoglobulin-like receptor 3 (LMIR3)) suppresses immunoglobulin E-dependent and mast cell-dependent allergic responses by b...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853571/ https://www.ncbi.nlm.nih.gov/pubmed/25673319 http://dx.doi.org/10.1136/gutjnl-2014-308900 |
_version_ | 1782430093744799744 |
---|---|
author | Matsukawa, Toshihiro Izawa, Kumi Isobe, Masamichi Takahashi, Mariko Maehara, Akie Yamanishi, Yoshinori Kaitani, Ayako Okumura, Ko Teshima, Takanori Kitamura, Toshio Kitaura, Jiro |
author_facet | Matsukawa, Toshihiro Izawa, Kumi Isobe, Masamichi Takahashi, Mariko Maehara, Akie Yamanishi, Yoshinori Kaitani, Ayako Okumura, Ko Teshima, Takanori Kitamura, Toshio Kitaura, Jiro |
author_sort | Matsukawa, Toshihiro |
collection | PubMed |
description | OBJECTIVE: Extracellular ATP mediates mast cell-dependent intestinal inflammation via P2X7 purinoceptors. We have previously shown that CD300f (also called the leucocyte mono-immunoglobulin-like receptor 3 (LMIR3)) suppresses immunoglobulin E-dependent and mast cell-dependent allergic responses by binding to ceramide. The aim of the present study was to clarify the role of ceramide–LMIR3 interaction in the development of IBD. DESIGN: The dextran sodium sulfate (DSS)-induced colitis model was used in wild-type (WT), LMIR3(−/−), mast cell-deficient Kit(W-sh/W-sh), Kit(W-sh/W-sh)LMIR3(−/−) or Kit(W-sh/W-sh) mice engrafted with WT or LMIR3(−/−) bone marrow-derived mast cells (BMMCs). The severity of colitis was determined by clinical and histological criteria. Lamina propria cell populations were assessed by flow cytometry. Production of chemical mediators from lamina propria cells was measured by real-time reverse transcription PCR. Production of chemical mediators from ATP-stimulated BMMCs in the presence or absence of ceramide was measured by ELISA. The severity of DSS-induced colitis was assessed in mice given either an Fc fusion protein containing an extracellular domain of LMIR3, and anticeramide antibody, or ceramide liposomes. RESULTS: LMIR3 deficiency exacerbated DSS-induced colitis in mice. Kit(W-sh/W-sh) mice harbouring LMIR3(−/−) mast cells exhibited more severe colitis than those harbouring WT mast cells. Ceramide–LMIR3 interaction inhibited ATP-stimulated activation of BMMCs. DSS-induced colitis was aggravated by disrupting the ceramide–LMIR3 interaction, whereas it was suppressed by treating with ceramide liposomes. CONCLUSIONS: LMIR3-deficient colonic mast cells were pivotal in the exacerbation of DSS-induced colitis in LMIR3(−/−) mice. Ceramide liposomes attenuated DSS-induced colitis by inhibiting ATP-mediated activation of colonic mast cells through ceraimide–LMIR3 binding. |
format | Online Article Text |
id | pubmed-4853571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-48535712016-05-06 Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation Matsukawa, Toshihiro Izawa, Kumi Isobe, Masamichi Takahashi, Mariko Maehara, Akie Yamanishi, Yoshinori Kaitani, Ayako Okumura, Ko Teshima, Takanori Kitamura, Toshio Kitaura, Jiro Gut Inflammatory Bowel Disease OBJECTIVE: Extracellular ATP mediates mast cell-dependent intestinal inflammation via P2X7 purinoceptors. We have previously shown that CD300f (also called the leucocyte mono-immunoglobulin-like receptor 3 (LMIR3)) suppresses immunoglobulin E-dependent and mast cell-dependent allergic responses by binding to ceramide. The aim of the present study was to clarify the role of ceramide–LMIR3 interaction in the development of IBD. DESIGN: The dextran sodium sulfate (DSS)-induced colitis model was used in wild-type (WT), LMIR3(−/−), mast cell-deficient Kit(W-sh/W-sh), Kit(W-sh/W-sh)LMIR3(−/−) or Kit(W-sh/W-sh) mice engrafted with WT or LMIR3(−/−) bone marrow-derived mast cells (BMMCs). The severity of colitis was determined by clinical and histological criteria. Lamina propria cell populations were assessed by flow cytometry. Production of chemical mediators from lamina propria cells was measured by real-time reverse transcription PCR. Production of chemical mediators from ATP-stimulated BMMCs in the presence or absence of ceramide was measured by ELISA. The severity of DSS-induced colitis was assessed in mice given either an Fc fusion protein containing an extracellular domain of LMIR3, and anticeramide antibody, or ceramide liposomes. RESULTS: LMIR3 deficiency exacerbated DSS-induced colitis in mice. Kit(W-sh/W-sh) mice harbouring LMIR3(−/−) mast cells exhibited more severe colitis than those harbouring WT mast cells. Ceramide–LMIR3 interaction inhibited ATP-stimulated activation of BMMCs. DSS-induced colitis was aggravated by disrupting the ceramide–LMIR3 interaction, whereas it was suppressed by treating with ceramide liposomes. CONCLUSIONS: LMIR3-deficient colonic mast cells were pivotal in the exacerbation of DSS-induced colitis in LMIR3(−/−) mice. Ceramide liposomes attenuated DSS-induced colitis by inhibiting ATP-mediated activation of colonic mast cells through ceraimide–LMIR3 binding. BMJ Publishing Group 2016-05 2015-02-11 /pmc/articles/PMC4853571/ /pubmed/25673319 http://dx.doi.org/10.1136/gutjnl-2014-308900 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Inflammatory Bowel Disease Matsukawa, Toshihiro Izawa, Kumi Isobe, Masamichi Takahashi, Mariko Maehara, Akie Yamanishi, Yoshinori Kaitani, Ayako Okumura, Ko Teshima, Takanori Kitamura, Toshio Kitaura, Jiro Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation |
title | Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation |
title_full | Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation |
title_fullStr | Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation |
title_full_unstemmed | Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation |
title_short | Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation |
title_sort | ceramide-cd300f binding suppresses experimental colitis by inhibiting atp-mediated mast cell activation |
topic | Inflammatory Bowel Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853571/ https://www.ncbi.nlm.nih.gov/pubmed/25673319 http://dx.doi.org/10.1136/gutjnl-2014-308900 |
work_keys_str_mv | AT matsukawatoshihiro ceramidecd300fbindingsuppressesexperimentalcolitisbyinhibitingatpmediatedmastcellactivation AT izawakumi ceramidecd300fbindingsuppressesexperimentalcolitisbyinhibitingatpmediatedmastcellactivation AT isobemasamichi ceramidecd300fbindingsuppressesexperimentalcolitisbyinhibitingatpmediatedmastcellactivation AT takahashimariko ceramidecd300fbindingsuppressesexperimentalcolitisbyinhibitingatpmediatedmastcellactivation AT maeharaakie ceramidecd300fbindingsuppressesexperimentalcolitisbyinhibitingatpmediatedmastcellactivation AT yamanishiyoshinori ceramidecd300fbindingsuppressesexperimentalcolitisbyinhibitingatpmediatedmastcellactivation AT kaitaniayako ceramidecd300fbindingsuppressesexperimentalcolitisbyinhibitingatpmediatedmastcellactivation AT okumurako ceramidecd300fbindingsuppressesexperimentalcolitisbyinhibitingatpmediatedmastcellactivation AT teshimatakanori ceramidecd300fbindingsuppressesexperimentalcolitisbyinhibitingatpmediatedmastcellactivation AT kitamuratoshio ceramidecd300fbindingsuppressesexperimentalcolitisbyinhibitingatpmediatedmastcellactivation AT kitaurajiro ceramidecd300fbindingsuppressesexperimentalcolitisbyinhibitingatpmediatedmastcellactivation |